Stockscreener 앱 받기
29.34
3.35%
0.95
시간 외 거래:
29.34
전일 마감가:
$28.39
열려 있는:
$28.28
하루 거래량:
1.23M
Relative Volume:
0.97
시가총액:
$2.99B
수익:
-
순이익/손실:
$-257.60M
주가수익비율:
-8.6294
EPS:
-3.4
순현금흐름:
$-220.31M
1주 성능:
+4.30%
1개월 성능:
-16.74%
6개월 성능:
+6.00%
1년 성능:
+166.24%
1일 변동 폭
$27.04
$29.66
1주일 범위
$27.04
$35.68
52주 변동 폭
$10.03
$47.45
다인 테라 Stock (DYN) Company Profile
명칭
Dyne Therapeutics Inc
전화
(781) 786-8230
주소
1560 TRAPELO ROAD, WALTHAM
DYN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| DYN | 29.34 | 2.99B | 0 | -257.60M | -220.31M | -3.40 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
다인 테라 Stock (DYN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-02-27 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | 개시 | Oppenheimer | Outperform |
| 2023-01-26 | 개시 | Guggenheim | Buy |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Outperform |
| 2020-10-12 | 개시 | JP Morgan | Overweight |
| 2020-10-12 | 개시 | Jefferies | Buy |
| 2020-10-12 | 개시 | Piper Sandler | Overweight |
| 2020-10-12 | 개시 | Stifel | Buy |
모두보기
다인 테라 주식(DYN)의 최신 뉴스
Dyne therapeutics director Jason Rhodes sells $25,884 in stock - Investing.com
Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Acquired by US Bancorp DE - Defense World
HC Wainwright Predicts Weaker Earnings for Dyne Therapeutics - MarketBeat
Chardan Capital Expects Lower Earnings for Dyne Therapeutics - MarketBeat
Short Interest in Dyne Therapeutics, Inc. (NASDAQ:DYN) Increases By 9.1% - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Trading Down 7.1%Time to Sell? - MarketBeat
RA Capital Management, L.P. Expands Stake in Dyne Therapeutics I - GuruFocus.com
Janus Henderson Group PLC's Strategic Acquisition in Dyne Therap - GuruFocus.com
Dyne Therapeutics (NASDAQ:DYN) Shares Gap DownTime to Sell? - MarketBeat
Deep Track Capital, LP Reduces Stake in Dyne Therapeutics Inc - GuruFocus.com
RTW INVESTMENTS, LP Expands Stake in Dyne Therapeutics Inc - GuruFocus.com
Dyne Therapeutics Reveals Q3 Results and Trial Updates - TipRanks
Dyne Therapeutics (NASDAQ:DYN) Given Buy Rating at HC Wainwright - MarketBeat
FMR LLC Bolsters Position in Dyne Therapeutics Inc with Signific - GuruFocus.com
Dyne Therapeutics Inc Reports Q3 2024 EPS of -$0.96, Missing Est - GuruFocus.com
Dyne Therapeutics Inc (DYN) Quarterly 10-Q Report - Quartz
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Dyne Therapeutics' DMD Drug Shows Promise; $723.7M Cash Position Fuels Clinical Progress | DYN Stock News - StockTitan
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely - Simply Wall St
Lisanti Capital Growth LLC Has $622,000 Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Dyne Therapeutics Inc. (DYN) Quarterly 10-Q Report - Quartzy
Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives $50.60 Average Price Target from Brokerages - MarketBeat
Creative Planning Has $381,000 Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World
Dyne Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Dyne Therapeutics to Present at Three Major Healthcare Investor Conferences | DYN Stock News - StockTitan
Dyne Therapeutics Enters Oversold Territory (DYN) - Nasdaq
Vanguard Group Inc's Strategic Acquisition in Dyne Therapeutics Inc - GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - PR Newswire
How the (DYN) price action is used to our Advantage - Stock Traders Daily
Dyne Therapeutics (DYN) Stock Dips Amidst Financial Report Insig - GuruFocus.com
Dyne cut to neutral by J.P. Morgan on stock's outperformance (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (NASDAQ:DYN) Downgraded by JPMorgan Chase & Co. to "Neutral" - MarketBeat
Dyne Therapeutics director Kersten Dirk sells shares totaling $475,878 - Investing.com India
Dyne Therapeutics director Kersten Dirk sells shares totaling $475,878 By Investing.com - Investing.com South Africa
Dyne Therapeutics (DYN) Shares Plummet Amid Market Volatility - GuruFocus.com
Where are the Opportunities in (DYN) - Stock Traders Daily
Dyne Therapeutics director Kersten Dirk sells $1.29 million in stock By Investing.com - Investing.com Australia
Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten Sells 23,671 Shares - MarketBeat
Dyne Therapeutics, Inc. (NASDAQ:DYN) Short Interest Update - MarketBeat
Daily Market Movement: Dyne Therapeutics Inc (DYN) Sees a 0.84 Increase, Closing at 33.59 - The Dwinnex
Dyne Therapeutics Inc (DYN) did well last session? - US Post News
Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Dyne Therapeutics’ DYNE-302 normalizes muscular pathology in preclinical FSHD - BioWorld Online
Selling Buzz: Dyne Therapeutics Inc [DYN] Director Kersten Dirk sells 21,518 shares of the company - Knox Daily
Trend Tracker for (DYN) - Stock Traders Daily
Dyne Therapeutics showcases clinical data at World Muscle Society Congress - Investing.com
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases - The Manila Times
Dyne Therapeutics Presents Data at World Muscle Society - GlobeNewswire
다인 테라 (DYN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):